Matthew MacEwan

Stories

FDA clears combined use of Solventum's Restrata matrix and V.A.C. therapy

Active

The U.S. Food and Drug Administration cleared Solventum to use its Restrata synthetic tissue matrix with its V.A.C. negative pressure wound therapy on October 19, 2026, the first clearance combining the two. Clinicians can place a fully synthetic, resorbable scaffold under a vacuum dressing that stays on for up to seven days.

Updated 3 hours ago